Your Comprehensive Guide to Dry AMD & GA Preclinical Therapeutics Development
Thank you to our speakers, sponsors, and delegates who joined us in XXX for the summit!
If you are interested in the 2024 event, please get in touch at info@hansonwade.com
The 5th Dry AMD & GA Therapeutics Summit returned to tackle key challenges facing discovery and translational scientists. Built with the industry’s specific needs in mind, 2024's agenda spanned discovery to early clinical content. This was your one stop shop to advance and accelerate the development of safe, effective and accessible dry AMD & GA therapeutics by uncovering cutting-edge advances.
Robust new content for 2024 included overcoming the major preclinical challenges including new preclinical models recapitulating retinal microenvironment, validating new drug targets beyond complement and inflammasome systems, identifying novel imaging biomarkers, and regulatory enabled clinical endpoints for faster approvals!
Top 5 Unmissable Highlights from 2024:
Accelerated ophthalmic drug delivery from oral and topical cell and gene therapy, for longer lasting, less invasive deliveries with Sanofi, Genentech and GelMEDIX
Leveraged AI models to develop imaging biomarkers and endpoints for earlier detection of macular degeneration with Apellis
Examined utilizing genomics, proteomics and histological studies to identify therapeutic targets and back translate clinical data with AbbVie, Sanofi and Aviceda
Optimized phase 1 clinical trial execution with novel regulatory approved endpoints, retinal imaging and appropriate patient selection with Genetech
Delved into innovations in gene and cell therapy from spatiallytargeted laser gene delivery to cell replacement therapy with Nanoscope Therapeutics and GelMEDIX
Who Attended in 2024?
Connect with senior biopharma leaders from Apellis, Boehringer Ingelheim, AbbVie, Genentech, Sanofi, Novartis, Aviceda, ONL Therapeutics
What Your Peers Have to Say:
‘’Focused discussion, building up new networks, and sharing cutting-edge sciences’’
Scientist, National Eye Institute
‘‘Almost complete coverage of assets under development and great forthrightness of the presenting speakers’’
Chief Executive Officer, Drusolv
‘’Generally excellent presentations but the most important are the Q&A discussions. People were open to learn and teach each other.’’
Chief Scientific Advisor, Tacit Therapeutics